Page 24 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

Erlotinib Promising for Cancer Prevention in FAP

Findings from this phase 2 trial support further study of erlotinib as "an effective, acceptable cancer preventive agent for FAP-associated gastrointestinal polyposis," the study team says. ....

United States , Niloy Jewel Samadder , Mayo Clinic , Medscape Medical , Colorectal Cancer , Antineoplastic Drug , Nti Cancer Agents , Familial Adenomatous Polyposis , Colonic Polyp , Alignant Neoplasia , Egfr Inhibitor , Pidermal Growth Factor Receptor Inhibitor , Genetic Disorder , Genomic Medicine , Edicine Genomic , Colon Cancer , Alignant Colon Neoplasm ,

Lung Adverse Effects in Patients Taking Trastuzumab Deruxtecan

Cancer patients treated with the targeted agent need to be closely monitored for interstitial lung disease/pneumonitis as an adverse event, say researchers reporting a new analysis. ....

New York , United States , Charles Powell , Coleman Icahn School Of Medicine , Coleman Icahn School , Patient Safety , Interstitial Lung Disease , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Inpatient Care , Adverse Effects , Side Effects , Antineoplastic Drug , Nti Cancer Agents ,

Does PREDICT Accurately Estimate Breast Cancer Survival?

A study coordinated by Italian researchers investigated the prognostic performance of PREDICT in patients with early-stage HER2-positive breast cancer. ....

Matteo Lambertini , Martino Polyclinic Hospital , Breast Cancer , Alignant Breast Neoplasm , Her2 Positive Breast Cancer , Her2 Breast Cancer , Antineoplastic Drug , Nti Cancer Agents ,

FDA Approves Enhertu (Trastuzumab Deruxtecan) for HER2 Lung Cancer

The agency has granted an accelerated approval for trastuzumab deruxtecan (Enhertu) to be used in patients with metastatic non–small cell lung cancer whose tumors have HER2 mutations. ....

Dave Fredrickson , Solange Peters , Antonio Passaro , Life Technologies Corporation Oncomine Dx Target Test , Guardant Health , Lausanne University Hospital , Drug Administration , European Institute Of Oncology , Life Technologies Corporation , Oncomine Dx Target Test , Oncology Business Unit , Data Welcomed , New England Journal , European Institute , Lung Cancer , Ung Carcinoma , Ancer Lung , Her2 Neu , Non Small Cell Lung Cancer , Tobacco Cessation , Uitting Tobacco Use , Gastric Cancer , Alignant Stomach Neoplasm , Noncolorectal Gastrointestinal Cancer , Oncolorectal Gi Cancer , Antineoplastic Drug ,

ACR Makes Changes to Adult, Pediatric Vaccinations Guidance

The pneumococcal, recombinant zoster, and HPV vaccines are among those recommended for patients taking immunosuppressive medications. ....

American College Of Rheumatology , American College , Pediatric Vaccines , Influenza Vaccine , Flu Vaccine , Influenza Vaccination , Flu Vaccination , Antineoplastic Drug , Nti Cancer Agents , Clinical Guidelines , Calcineurin Inhibitor , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronav ,